In the News

New algorithm may help physicians set glycemic targets for patients with diabetes

Researchers created a new algorithm to help choose target HbA1cs for patients with diabetes and compared the results to experts' advice.

Mortality in diabetes may vary greatly by age, glycemic control, renal complications

Patients who were under age 55 faced a more substantial increase in mortality risk from having diabetes than older patients.

DPP-4 inhibitors associated with lower mortality and cardiac risk than sulfonylureas as add-on therapy, study finds

When added to metformin, DPP-4 inhibitors were associated with reduced risks for all-cause death and stroke but did not appear to alter the risks for myocardial infarction and hospitalization for heart failure relative to sulfonylureas.

MKSAP quiz: Managing cardiovascular risk in diabetes patient

This month's quiz asks readers to evaluate a 72-year-old woman with hypertension, type 2 diabetes mellitus, and hyperlipidemia for sharp chest pain that occurs randomly.

Drinking wine associated with slightly improved cardiometabolic risk in type 2 diabetes patients

Cholesterol markers improved in patients with type 2 diabetes who were assigned to drink wine, and some patients also saw glycemic benefits, a recent study found.

Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea

Patients who took sitagliptin were significantly less likely to have hypoglycemia during Ramadan, according to a systematic review.

Physicians may overtreat blood pressure, glucose in older patients with diabetes

A retrospective cohort study used data from the Department of Veterans Affairs to assess both hypertension and blood glucose medication deintensification (i.e., dosage reduction or withdrawal of a drug).

Task Force recommends screening for type 2 diabetes in overweight, obese adults

The U.S. Preventive Services Task Force now recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in overweight and obese adults ages 40 to 70 years.

Spotlight on liraglutide and insulin

The effects of adding liraglutide to insulin treatment were assessed by multiple studies published in the past month.

Correction to October 2015 issue

In last month's issue, the article “Empagliflozin associated with reduced mortality risk in patients with cardiovascular disease” contained errors.